UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042951
Receipt number R000049034
Scientific Title A Study to Evaluate the Effect of Enzyme-treated Royal Jelly Consumption on the Index of Hematopoietic Stem Cell Count in Healthy Subjects
Date of disclosure of the study information 2021/06/30
Last modified on 2021/03/24 08:55:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Study to Evaluate the Effect of Enzyme-treated Royal Jelly Consumption on the Index of Hematopoietic Stem Cell Count in Healthy Subjects

Acronym

A Study to Evaluate the Effect of Enzyme-treated Royal Jelly Consumption on the Index of Hematopoietic Stem Cell Count in Healthy Subjects

Scientific Title

A Study to Evaluate the Effect of Enzyme-treated Royal Jelly Consumption on the Index of Hematopoietic Stem Cell Count in Healthy Subjects

Scientific Title:Acronym

A Study to Evaluate the Effect of Enzyme-treated Royal Jelly Consumption on the Index of Hematopoietic Stem Cell Count in Healthy Subjects

Region

Japan


Condition

Condition

Adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The test object will be ingested by healthy adults over a period of four weeks, and the effect on the number of hematopoietic stem cells in the peripheral blood will be examined.
To analyze the effect of enzyme-treated royal jelly on the number of hematopoietic stem cells in the peripheral blood

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Hematopoietic stem cell count (CD34+CD45dim cells)

Key secondary outcomes

Endothelial stem cell count (CD34+CD45-CD157+ cells), Endothelial progenitor cell count (CD31+CD34+CD45- cells)

Serum cytokines (CXCL12 and M-CSF)

Hematological examination (WBC, NEU, EOS, BAS, MON, RBC and PLT)

B cell count (CD19+ cells), NK cell count (CD56+ cells), CD4+ T cell count, CD8+ T cell count and CD8+CD28+ T cell count

Questionnaire evaluation (Chalder Fatigue Scale, Pittsburgh Sleep Questionnaire, and other 13-item VAS evaluation)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Functional food
Intake:2368.8 mg
Ingesion:28 day

Interventions/Control_2

Placebo food
Intake:2368.8 mg
Ingesion:28 day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Healthy males and females who are at least 20 years old at the time of obtaining consent
2) Those who can understand and comply with the administration during the study.
3) Those who have obtained written consent of their own free will to participate in the study after fully understanding the contents of the study.
4) Those who are deemed eligible by the study physician and others based on their overall judgment.

Key exclusion criteria

1) Subjects with a history of food allergy
2) Subjects with a history of asthma
3) Pregnant women, those who wish to become pregnant, and those who are breast-feeding
4) Those who have participated in other clinical studies within 12 weeks prior to the intake of the test food.
5) Those with a history of major surgery in the gastrointestinal tract, such as gastrectomy, gastrointestinal suture, or intestinal resection (appendicectomy is acceptable)
6) Subjects suffering from serious hepatic disorder, renal/cardiac disease, organ disorder, diabetes, autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, or other serious disease
7) Those who are receiving medication (hospital visits or medication prescriptions)
8) Those who are unable to consume test foods as instructed or are unable to maintain rest until the end of the test.
9) Those who are unable to prohibit the daily intake of foods that may affect the test.
10) Those who are unable to maintain a regular lifestyle
11) Those who do not work day shifts (night shifts or rotating shifts)
12) Those who have had blood drawn (e.g., donated blood) in excess of 200 mL within 4 weeks prior to the start of this study or 400 mL within 3 months
13) Those whose normal alcohol consumption exceeds 500 mL of beer equivalent per day.
14) Smokers
15) Subjects with a BMI of less than 18.5 and more than 30 kg/m2 (during the study period)
16) Those who cannot follow the instructions to wear a mask when visiting the hospital
17) Those who have cold symptoms such as fever, taste or smell disorder within 1 week of each observation point
18) Those who have had contact with COVID-19 patients or close contacts within 2 weeks of each observation point
19) Persons who have traveled to or had contact with foreign countries within 2 weeks of each observation point.
20) Other persons who are judged by the investigator to be inappropriate for participation in this study.

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Nobuaki
Middle name
Last name Okumura

Organization

Yamada Bee Company, Inc.

Division name

Functional research section, Institute for Bee Products & Health Science, R&D department

Zip code

708-0393

Address

194 Ichiba, Kagamino-cho, Tomata-gun, Okayama 708-0393 Japan

TEL

0868-54-3825

Email

no1780@yamada-bee.com


Public contact

Name of contact person

1st name Hideto
Middle name
Last name Okamoto

Organization

Yamada Bee Company, Inc.

Division name

Functional research section, Institute for Bee Products & Health Science, R&D department

Zip code

708-0393

Address

194 Ichiba, Kagamino-cho, Tomata-gun, Okayama 708-0393 Japan

TEL

0868-54-3825

Homepage URL


Email

ho1993@yamada-bee.com


Sponsor or person

Institute

Yamada Bee Company, Inc.

Institute

Department

Personal name



Funding Source

Organization

Yamada Bee Company, Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Research Center for Immunological Analysis, Inc.

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shiba Palace Clinic Ethics Review Committee

Address

DaiwaA Hamamatsucho Bldg. 6F, 1-9-10, Hamamatsucho, Minato-ku, Tokyo, 105-0013, JAPAN

Tel

03-5408-1599

Email

shiba_palace@s-palace-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 06 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 12 Month 15 Day

Date of IRB

2020 Year 12 Month 25 Day

Anticipated trial start date

2021 Year 01 Month 12 Day

Last follow-up date

2021 Year 03 Month 19 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 01 Month 08 Day

Last modified on

2021 Year 03 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049034


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name